Recent Updates
Recently added Catalysts

LY3549492

Phase 2

Obesity | Small molecule | Metabolic |Eli Lilly and Company|Last Updated: May 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment288
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06683508A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightPHASE2 COMPLETED 288 — — Nov 13, 2024May 4, 2026May 13, 202649 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Change from Baseline in Body Weight
Baseline, Week 36
Secondary Endpoints
Change from Baseline in Body Weight (kilograms)
Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Baseline, Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Baseline, Week 36
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
LY3549492 Dose 1EXPERIMENTALParticipants will receive LY3549492 orally
LY3549492 Dose 2EXPERIMENTALParticipants will receive LY3549492 orally
LY3549492 Dose 3EXPERIMENTALParticipants will receive LY3549492 orally
LY3549492 Dose 4EXPERIMENTALParticipants will receive LY3549492 orally
LY3549492 Dose 5EXPERIMENTALParticipants will receive LY3549492 orally
PlaceboPLACEBO_COMPARATORParticipants will receive Placebo orally
Interventions
NameTypeDescription
LY3549492DRUGAdministered orally
PlaceboDRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites49

Inclusion Criteria: W8M-MC-GN01: * Assigned male at birth * Assigned female at birth, who are of non-childbearing potential W8M-MC-CWMM: * Have a BMI of * ≥ 30 kilograms per square meter (kg/m²) or * ≥ 27 kg/m² and \< 30 kg/m² with at least one weight-related comorbidity * Have had a stable...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Obesity 202 trials
CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY43PHASE3Retatrutide, Orforglipron, Tirzepatide, Ixekizumab, Eloralintide
Amgen Inc.AMGN10PHASE3Maridebart cafraglutide, Maridebart Cafraglutide, Moxifloxacin, COC
Novo Nordisk A/S Sponsored ADR Class BNVO47PHASE3Cagrilintide, Semaglutide, Liraglutide, CagriSema, NNC0487-0111
Rhythm Pharmaceuticals, Inc.RYTM8PHASE3Setmelanotide, Bivamelagon, Part C: RM-718, Part D: RM-718
Pfizer Inc.PFE2PHASE3PF-08653944
Regeneron Pharmaceuticals, Inc.REGN3PHASE3Mibavademab, Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
AstraZeneca PLCAZN3PHASE2AZD6234, AZD9550, Plocebo
Kailera Therapeutics, Inc.KLRA4PHASE3KAI-9531, Semaglutide, KAI-7535
Structure Therapeutics, Inc. Sponsored ADRGPCR3PHASE2Aleniglipron
PfizerMTSR3PHASE3MET097, MET233 and MET097
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab, semaglutide
Palatin Technologies, IncPTN1PHASE2bremelanotide, tirzepatide
Veru IncVERU1PHASE2Enobosarm, Semaglutide weekly
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE1ARO-INHBE, Tirzepatide, ARO-ALK7
Alnylam Pharmaceuticals, IncALNY1PHASE1ALN-2232, Tirzepatide
Gilead Sciences, Inc.GILD1PHASE1GS-4571, Omeprazole
AbbVie, Inc.ABBV1PHASE1ABBV-295
MBX Biosciences, Inc.MBX1PHASE1MBX 4291
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
HIGHMay 26, 2026NCT06683508Status: ACTIVE_NOT_RECRUITING → COMPLETED
LOWMay 24, 2026NCT06683508studyFirstPostDate: changed